INTERIM REPORT JANUARY-SEPTEMBER 2009 TRIPEP AB (PUBL)
Research and development costs amounted to SEK 4.5 (14.5) m The loss after tax was SEK -8.7 (-23.5) m Earnings per share were SEK -0.33 (-2.38) Net sales SEK 0.4 (-) m The company has carried out two private placements raising SEK 6 m through the placements The ChronVac-C® study is progressing according to plan and a final report is expected during the fourth quarter this year The multi-center study on ChronSeal® is ongoing in Sweden and Norway. An interim analysis of the treatment effect will be performed no later than October 31st and published shortly thereafter Tripep has out licensed the RAS® technology to Opsonic Therapeutics For more information, please contact: Anders Vahlne, CEO & Head of Research, Tripep AB Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28 E-mail: firstname.lastname@example.org About Tripep Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal® and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company’s website: www.tripep.se. In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.